代謝型グルタミン酸受容体2の世界市場:パイプラインレビュー(2019上半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA906A242)
◆英語タイトル:Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2019
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA906A242
◆発行日:2019年5月21日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥742,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD10,500 ⇒換算¥1,113,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[代謝型グルタミン酸受容体2の世界市場:パイプラインレビュー(2019上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Metabotropic Glutamate Receptor 2 – Pipeline Review, H1 2019
Summary

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 7 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Treatment Resistant Depression, Depression, Drug Addiction, Psychosis, Schizophrenia, Anxiety Disorders, Epilepsy, Ischemia, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Post-Traumatic Stress Disorder (PTSD) and Stroke.

The latest report Metabotropic Glutamate Receptor 2 – Pipeline Review, H1 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
- The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Overview
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Johnson & Johnson
Mediti Pharma Inc
Merck & Co Inc
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Drug Profiles
ADX-92639 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMT-133218 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-40411813 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5515 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-341495 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-0069330 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGlu2 for Anxiety and Depression – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Dormant Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Discontinued Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Product Development Milestones
Featured News & Press Releases
Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy
Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD
Feb 27, 2017: Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms
Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia
Sep 02, 2010: Addex’s mGluR2 Shows Efficacy In Alzheimer’s Disease Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Addex Therapeutics Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Camino Pharma LLC, H1 2019
Pipeline by Denovo Biopharma LLC, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by Johnson & Johnson, H1 2019
Pipeline by Mediti Pharma Inc, H1 2019
Pipeline by Merck & Co Inc, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019

*** 掲載企業 ***

Addex Therapeutics Ltd、Bristol-Myers Squibb Co、Camino Pharma LLC、Denovo Biopharma LLC、Eli Lilly and Co、Johnson & Johnson、Mediti Pharma Inc、Merck & Co Inc

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 自律モバイルロボットの世界市場2017-2021
    About Autonomous Mobile Robots Autonomous mobile robots are the unmanned automated units that are capable of performing tasks on their own with minimal manual supervision. These robots are untethered and operate on an autonomous energy source. Autonomous mobile robots are of three types: unmanned ma …
  • オートビューティーの世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2021)
    Auto Beauty refers to the various parts of different materials for the automotive maintenance required conditions, using beauty care products and construction technology to care and maintenance for cars. This report include the products of auto beauty, like cleaning & caring products, polishing & wa …
  • ブートショックアブソーバーの世界市場2018
    Boot Shock Absorber Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Ge …
  • 世界及び中国の三塩化シラン市場2017
    The 'Global and Chinese Trichlorosilane Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Trichlorosilane industry with a focus on the Chinese market. The report provides key statistics on the market status of the Trichlorosilane manu …
  • グリコールの世界市場:製品別(エチレン、プロピレン)、用途別(自動車、HVAC、繊維、ポリエステル繊維・樹脂、航空会社)、セグメント予測
    The global glycols market size is projected to reach USD 47.26 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 6.7% during the forecast period. Recovering end-use industries in developed nations is a key driving factor for the market. Ethylene glycol …
  • ベルギー のヒ素市場2016-2020
    About The report brings together facts and figures about arsenic market in Belgium covering period of 2010-2020. Statistics, experts’ opinions and estimations are given. The report about arsenic market in Belgium covers: - reserves, mines, production - manufacturers - demand structure, trends - cons …
  • 紫外線LED(UV-LED)技術の世界市場2018-2022
    About this market The continuously increasing innovations in the UV LEDs is expected to gain significant traction in the market. The ability of UV LEDs to consume upto 70% less energy than conventional CFLs is expected to encourage vendors in innovating with LEDs owing to features including small si …
  • ポリフェニレンの世界市場
    Amid the COVID-19 crisis, the global market for Polyphenylene estimated at US$3.5 Billion in the year 2020, is projected to reach a revised size of US$5.7 Billion by 2027, growing at a CAGR of 7% over the analysis period 2020-2027.PPS, one of the segments analyzed in the report, is projected to grow …
  • 世界のラウロイルグリシン市場予測 2020年-2025年
    COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin Ameri …
  • カルシウムの世界市場予測2018-2023
    Calcium is a chemical element with symbol Ca and atomic number 20. An alkaline earth metal, calcium is a reactive metal that forms a dark oxide-nitride layer when exposed to air. Its physical and chemical properties are most similar to its heavier homologues strontium and barium. Of the key end use …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA906A242 )"代謝型グルタミン酸受容体2の世界市場:パイプラインレビュー(2019上半期)" (英文:Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2019)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。